Categories Health Care

Solid Biosciences tumbles 38% to hit historic low

Shares of Solid Biosciences Inc. (NASDAQ: SLDB) opened 38% lower on Tuesday after the company said in its first-quarter results that its lead investigational drug, SGT-001, spurred serious adverse event in a patient.

The drug has been in development to treat a rare muscle disorder known as Duchenne. However, in its latest patient, the drug caused certain liver problems, besides gastrointestinal infection.

Image for representation (Photo by Drew Hays on Unsplash)

Solid Biosciences added that the patient is currently doing well and has resumed normal activities.    

The company, which does not have any revenues as of now, said its research and development expenses doubled during the quarter to $23.3 million, all attributable to SGT-001.

Net loss almost doubled to $29.6 million, or 85 cents per share, hurt by the higher expenses.

READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS

The company, which started trading in January last year, has since declined 62% and is currently trading at an all-time low.

CEO Ilan Ganot said, “We have continued to advance our programs for Duchenne muscular dystrophy over the last few months, particularly our lead microdystrophin gene therapy candidate, SGT-001. Building on our findings from the preliminary Phase I/II clinical data that we announced in February, we initiated dosing at 2E14 vg/kg in the second cohort of patients.”

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top